Abstract
INTRODUCTION: Cancer is a major health problem worldwide, and the most extensive treatment can be obtained by using chemotherapy in the clinic. However, due to the low selectivity of cancer cells, chemotherapy drugs produce a series of grievous side effects on normal cells. METHODS: In this research, we developed novel nanocarriers for magnetically targeted near-infrared (NIR) light-electromagnetic wave dual controlled drug delivery based on MgFe(2)O(4)@CuS nanoparticles (NPs) modified with aminopropyltriethoxysilane (APTES) in response to magnetic, NIR light, and electromagnetic wave irradiation. Synthesis and characterization of MgFe(2)O(4)@CuS-APTES NPs was carried out using X-ray diffraction measurements, scanning electron microscopy, transmission electron microscopy, photoluminescence emission spectra, UV-1800 spectrophotometer, N5230A vector network analyzer, MDS-6 microwave sample preparation system, and superconducting quantum interference device. In addition to that mentioned above, we also explored many other sides, such as the drug-loading, drug-controlled release efficiency, elect99omagnetic wave thermal effect and photo-thermal effect. RESULTS: The results showed that APTES-modified MgFe(2)O(4)@CuS NPs had 37% high drug-loading capacity and high electromagnetic wave thermal conversion ability and NIR-light thermal conversion ability. In addition, ibuprofen (IBU) release from the MgFe(2)O(4)@CuS-APTES-IBU depends on the electromagnetic wave (2.45 GHz) and 1060 nm NIR light irradiation. After five cycles, the drug-release percentage was 90% and 66% separately, and could be adjusted by the time and cycles times of electromagnetic wave and NIR light irritation. Electromagnetic wave irradiation compared with NIR light irradiation, has a higher drug release rate and better penetration. Therefore, choosing different stimulation methods according to the treatment needs of the disease, we can achieve accurate personalized treatment of the disease. DISCUSSION: Our findings indicate that multifunctional APTES modified MgFe(2)O(4)@CuS NPs could be used for the first time as a new drug carrier for "location-timing-quantification" drug release with magnetic targeting and dual control of NIR light-electromagnetic waves.